Genome Editing Market Scope And Analysis

Report Code : TIPHE100000853
Category : Biotechnology

Status : Published
No. of Pages : 176

Buy Now

Genome Editing Market Scope and Key Players Analysis by 2028

Buy Now

Genome Editing Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 5.2 Billion
Market Size by 2028	US$ 16.99 Billion
Global CAGR (2021 - 2028)	18.4%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Technology CRISPR TALEN Antisense By Application Cell Line Engineering Genetic Engineering Diagnostic Applications Drug Discovery By End User Pharmaceutical and Biotechnology Companies Academic and Research Institutes Clinical Research Organizations
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	THERMO FISHER SCIENTIFIC INC MERCK KGaA Lonza Horizon Discovery Group plc Integrated DNA Technologies GenScript New England Biolabs Eurofins Scientific CRISPR Therapeutics

In November 2021, Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, has launched its rhAmpSeq CRISPR Analysis System, which offers an end-to-end solution for characterizing and quantifying the full array of on- and off-target genome editing events in CRISPR research projects.
In December 2021, Editas Medicine, Inc., a leading genome editing company, announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the Company to initiate a Phase 1/2 clinical study of EDIT-301 in TDT patients.
In August 2020, Horizon Discovery Group plc a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of single-cell RNA seq-linked pooled CRISPR screening to its CRISPR screening services portfolio. The platform offers high-quality screening data and biological insight to address critical gaps in target identification and validation.
In December 2021, Eurofins Scientific has agreed to acquire Japan-based testing services provider Genetic Lab (G Lab) from Transgenic for an undisclosed sum. G Lab is involved in delivering molecular biology based testing for diagnostics, biomarker development and drug discovery.
In May 2021, New England Biolabs, inc., a leading supplier of life science reagents, announced that it entered into an agreement to acquire Fluorogenics Limited (FGL), a lyophilization R&D service company based in the UK. Under the terms of the agreement, FGL will become a wholly-owned subsidiary of NEB.